Search company, investor...



Series C | Alive

Total Raised


Last Raised

$12M | 11 yrs ago

About Excelimmune

Excelimmune is a biopharmaceutical company specializing in the development of recombinant polyclonal antibodies to create novel therapies for treating disease in humans. This next generation technology is applicable to the treatment of diseases and infections caused by common bacteria, disease-causing proteins and viral pathogens.

Headquarters Location

519 Somerville Avenue PMB 214

Woburn, Massachusetts, 02143,

United States

Missing: Excelimmune's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Excelimmune's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Excelimmune

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Excelimmune is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Excelimmune Patents

Excelimmune has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Molecular biology, Immunology, Clusters of differentiation, Immune system, Transcription factors


Application Date


Grant Date



Related Topics

Molecular biology, Immunology, Clusters of differentiation, Immune system, Transcription factors



Latest Excelimmune News

Catalent Biologics Adds New Technology Platform to Enable Antibody Combination Therapies

Jul 7, 2015

Catalent, Inc. to Present at Two Investor Conferences in May Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has signed an exclusive licensing agreement with Excelimmune, Inc. to access its antibody combination therapy (ACT) technology platform. The platform has the potential to enable a consistent and cost-effective method to manufacture multiple recombinant antibodies or other recombinant proteins in a single batch culture. Under the licensing agreement, Catalent will continue development work on the platform, both internally and in conjunction with partner-sponsored programs. Catalent will also be able to leverage its own proprietary GPEx® technology to help enable that development. “Combination antibody therapies are becoming the treatment standard for many indications within oncology, immuno-oncology, and infectious diseases,” commented Mike Riley, Vice President/General Manager, Catalent Biologics. He added, “This technology platform has the potential to allow production of multiple antibodies in a significantly more cost-effective manner. This can allow innovators to look to combinations earlier in clinical development, and could be the difference in a new treatment getting to patients.” Excelimmune's antibody combination expression system is based on a key innovation: the use of stable pools of cells generated by multiple directed gene insertions, instead of clonal cell lines. This attribute contributes to a quick, stable, and flexible culture system for mixtures of cells producing different antibodies. This technology has the potential to pave the way for more consistent, cost-effective production of antibody combinations, which will allow complex antibody therapeutics to gain greater accessibility to the clinic. About Catalent Catalent, Inc. is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,600 people, including over 1,000 scientists, at 30 facilities across 5 continents, and in fiscal 2014 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit More products. Better treatments. Reliably supplied.™ For the original version on PRWeb visit:

Excelimmune Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Excelimmune Rank

Excelimmune Frequently Asked Questions (FAQ)

  • Where is Excelimmune's headquarters?

    Excelimmune's headquarters is located at 519 Somerville Avenue, Woburn.

  • What is Excelimmune's latest funding round?

    Excelimmune's latest funding round is Series C.

  • How much did Excelimmune raise?

    Excelimmune raised a total of $28.24M.

  • Who are the investors of Excelimmune?

    Investors of Excelimmune include Qualifying Therapeutic Discovery Project.

  • Who are Excelimmune's competitors?

    Competitors of Excelimmune include Armgo Pharma, Sorrento Therapeutics, Promedior, Fusion Antibodies, Sarentis Therapeutics and 11 more.

Compare Excelimmune to Competitors

Cerevast Therapeutics

Cerevast Therapeutics is developing a non-invasive treatment for acute ischemic stroke known as sonothrombolysis, or SonoLysis for short. This treatment harnesses the acoustic energy from externally applied ultrasound to treat stroke-causing clots in the blood vessels of the brain. The company has developed an operator-independent ultrasonic headframe called the ClotBust-ER. This device can be rapidly and easily deployed by virtually any emergency room staff to safely administer the ultrasound energy for SonoLysis therapy.


NeuroGenomeX is a drug discovery company developing novel treatments for diseases of the brain and nervous system. The current NeuroGenomeX discovery program is focused on therapeutic target areas of epilepsy and traumatic brain injury. NeuroGenomeX is advancing its lead drug candidate, 2-deoxy-D-glucose (2DG), as an anticonvulsant that stops seizures and has beneficial effects against adverse long-term consequences of epilepsy. 2DG also has shown favorable therapeutic neuroprotective effects in animal models of traumatic brain injury (TBI).

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.


Altus is focused on accelerating the development and commercialization of protein-based products through our Crystalomics technology platform. Crystalomics aims to rapidly turn proteins into products resulting in significant market benefits in Therapeutic, Diagnostic, and Industrial applications.

Trinity Biosystems

Trinity Biosystems is developing a platform technology for the delivery of peptides across intact mucosal surfaces. The initial therapeutic applications of the technology will focus on vaccines, where animal testing has demonstrated the potential to induce both systemic and mucosal immunity following delivery of various antigens. The company's first product to enter trials will be a vaccine for the prevention of Pseudomonas aeruginosa infections in Cystic Fibrosis (CF) patients. Subsequent products will address other infectious diseases and the company will also be exploring the potential of applying the technology to the oral delivery of other biopharmaceuticals. Despite the continued discovery of novel peptides for the treatment and prevention of human disease, many applications suffer because the optimal delivery technology remains a key missing link. Trinity is developing technology capable of transporting proteins, peptides and other macromolecules across intact mucosal barriers using endogenous epithelial cell pathways. This technology not only overcomes current limitations associated with protein and peptide transport, but also provides targeted delivery to specific cells of the body.

NeoClone Logo

NeoClone is a custom monoclonal antibody company focused on developing high quality antibodies for sale as reagents and establishing partnerships and collaborations to develop diagnostic mAbs.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.